Astellas Pharmaceuticals supplement to generics patent case halted by US district court
MLex Summary: A US federal court rejected an attempt by Astellas Pharmaceuticals to supplement its Abbreviated New Drug Application (ANDA) complaint against generic drug manufacturers into a traditional patent infringement case,...To view the full article, register now.
Already a subscriber? Click here to view full article